{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:58Z","timestamp":1791082018008,"version":"4.1.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The Roche prolactin immunoassay is used throughout the world. It reports higher values than the Siemens immunoassay but the manufacturer-defined reference intervals are similar. Patient results are often above the Roche upper limit but within the Siemens interval, causing diagnostic confusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Establish new reference intervals for the Roche and Siemens prolactin immunoassays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We established new reference intervals for the Roche and Siemens immunoassays using 374 specimens from healthy outpatients. We performed chart review for unnecessary testing and treatment for 298 patients in a 6-month period with at least 1 Roche prolactin value above the manufacturer-defined upper limit and below our new upper limit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The new upper limit for the Roche assay was 37.8\u2005ng\/mL (females) and 22.8\u2005ng\/mL (males). The manufacturer-defined limits were 23.3\u2005ng\/mL and 15.2\u2005ng\/mL, respectively. New intervals for the Siemens assay matched the manufacturer. No cases of clinically significant pathophysiologic prolactin excess were identified in patients with values between the manufacturer-defined upper reference limit and our new Roche upper limit. Unnecessary further evaluation in these patients included 459 repeat prolactin measurements, 57 macroprolactin measurements, 39 magnetic resonance imaging studies, and 28 endocrine referrals. Eleven patients received dopamine agonists. The minimum cost of excess care using Medicare reimbursement rates was $34\u2005134, with substantially higher amounts billed to patients and their insurance providers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adoption of new upper reference limits for the Roche prolactin assay of 37.8\u2005ng\/mL (females) and 22.8\u2005ng\/mL (males) would not delay diagnosis or necessary intervention in patients with clinically significant pituitary tumors but would reduce unnecessary evaluation in patients without pathophysiologic prolactin excess.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvae069","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T23:21:49Z","timestamp":1712618509000},"source":"Crossref","is-referenced-by-count":7,"title":["Clinical Impact of New Reference Intervals for the Roche Prolactin II Immunoassay"],"prefix":"10.1210","volume":"8","author":[{"given":"Erin","family":"Earll","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin , Milwaukee, WI 53226 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-3043","authenticated-orcid":false,"given":"Bradley R","family":"Javorsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin , Milwaukee, WI 53226 , USA"},{"name":"Clement J. Zablocki VA Medical Center , Milwaukee, WI 53295 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-489X","authenticated-orcid":false,"given":"Jenna","family":"Sarvaideo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin , Milwaukee, WI 53226 , USA"},{"name":"Clement J. Zablocki VA Medical Center , Milwaukee, WI 53295 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joely A","family":"Straseski","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah Health Sciences Center , Salt Lake City, UT 84112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2545-684X","authenticated-orcid":false,"given":"Robert D","family":"Nerenz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Medical College of Wisconsin , Milwaukee, WI 53226 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"2024050411512442400_bvae069-B1","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"J Reprod Med"},{"key":"2024050411512442400_bvae069-B2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin\u2014a pleiotropic factor in health and disease","volume":"15","author":"Bernard","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2024050411512442400_bvae069-B3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"2024050411512442400_bvae069-B4","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1073\/pnas.75.12.5946","article-title":"Estrogen control of prolactin synthesis in vitro","volume":"75","author":"Lieberman","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024050411512442400_bvae069-B5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","article-title":"Hyperprolactinemia: pathophysiology and therapeutic approach","volume":"31","author":"Capozzi","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"2024050411512442400_bvae069-B6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2024050411512442400_bvae069-B7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/15532739.2020.1819505","article-title":"Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: a systematic review","volume":"21","author":"Wilson","year":"2020","journal-title":"Int J Transgend Health"},{"key":"2024050411512442400_bvae069-B8","doi-asserted-by":"crossref","first-page":"913S","DOI":"10.3945\/ajcn.115.110379","article-title":"Progress in standardizing and harmonizing thyroid function tests12","volume":"104","author":"Faix","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"2024050411512442400_bvae069-B9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1373\/clinchem.2009.129205","article-title":"Characterization of the hCG variants recognized by different hCG immunoassays: an important step toward standardization of hCG measurements","volume":"55","author":"Gronowski","year":"2009","journal-title":"Clin Chem"},{"key":"2024050411512442400_bvae069-B10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jsbmb.2010.03.032","article-title":"Standardization of testosterone measurements in humans","volume":"121","author":"Vesper","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2024050411512442400_bvae069-B11","doi-asserted-by":"crossref","first-page":"e00065","DOI":"10.1002\/edm2.65","article-title":"Serum prolactin overestimation and risk of misdiagnosis","volume":"2","author":"Sousa","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"2024050411512442400_bvae069-B12","doi-asserted-by":"crossref","first-page":"MON-281","DOI":"10.1210\/jendso\/bvaa046.1857","article-title":"MON-281 A pilot study: comparing prolactin measurements between two different immunoassays","volume":"4","author":"Woznick","year":"2020","journal-title":"J Endocr Soc"},{"key":"2024050411512442400_bvae069-B13","author":"Elecsys Prolactin II Package Insert"},{"key":"2024050411512442400_bvae069-B14","author":"Prolactin (PRL) Package Insert"},{"key":"2024050411512442400_bvae069-B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0014-2964(77)90053-6","article-title":"Serum prolactin concentrations throughout the menstrual cycle of normal women and patients with recent breast cancer","volume":"13","author":"Cole","year":"1977","journal-title":"Eur J Cancer"},{"key":"2024050411512442400_bvae069-B16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2265.1976.tb03867.x","article-title":"Prolactin levels during the menstrual cycle","volume":"5","author":"Franchimont","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024050411512442400_bvae069-B17","unstructured":"Earll E, Javorsky B, Sarvaideo J, Straseski J, Nerenz R. 2024. Summary of Contraceptive Preparations in Ethinyl Estradiol Group [Internet]. Figshare. Posted and accessed February 6, 2024. http:\/\/doi.org\/10.6084\/m9.figshare.25153379"},{"key":"2024050411512442400_bvae069-B18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2024050411512442400_bvae069-B19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2517-6161.1964.tb00553.x","article-title":"Analysis of transformations","volume":"26","author":"Box","year":"1964","journal-title":"J R Stat Soc"},{"key":"2024050411512442400_bvae069-B20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/clinchem\/47.12.2137","article-title":"Effect of outliers and nonhealthy individuals on reference interval estimation","volume":"47","author":"Horn","year":"2001","journal-title":"Clin Chem"},{"key":"2024050411512442400_bvae069-B21","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/0009-8981(87)90151-3","article-title":"Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits","volume":"170","author":"Solberg","year":"1987","journal-title":"Clinica Chimica Acta"},{"key":"2024050411512442400_bvae069-B22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.18231\/j.ijcbr.2023.024","article-title":"Verification of Roche reference ranges for serum prolactin in children, adolescents, adults, and the elderly","volume":"10","author":"Ilardo","year":"2023","journal-title":"Int J Clin Biochem Res"},{"key":"2024050411512442400_bvae069-B23","volume-title":"Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory","author":"CLSI","year":"2010","edition":"3rd ed"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvae069\/57188704\/bvae069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/6\/bvae069\/57402050\/bvae069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/6\/bvae069\/57402050\/bvae069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T11:51:44Z","timestamp":1714823504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvae069\/7642642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvae069","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,6]]},"article-number":"bvae069"}}